Form 4: KORU Medical Systems CEO Linda Tharby Reports Stock Transactions
SEC Form 4
Linda Tharby, CEO of KORU Medical Systems, reports acquisition of shares as part of her bonus and disposition of shares for tax obligations.
Summary
- Linda Tharby, the President and CEO of KORU Medical Systems, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
- On March 13, 2024, she acquired 19,681 shares of common stock at a price of $2.09 per share as part of her employment agreement for a bonus, where 70% was paid in cash and 30% in shares.
- On the same day, she disposed of 7,094 shares at $2.09 per share to cover tax withholding obligations related to the bonus shares.
- Following these transactions, Tharby beneficially owns 1,069,443 shares of KORU Medical Systems stock.
- This total includes 200,000 restricted stock awards vesting annually until 4/12/25, 200,000 restricted stock awards vesting based on market capitalization targets by 3/15/27, and 600,000 restricted stock awards vesting based on net sales growth targets from 2022-2025.
Sentiment
Score: 6
Explanation: Neutral sentiment as the filing reflects routine transactions related to executive compensation and tax obligations. The CEO's continued holding of a significant number of shares is a moderately positive sign.
Positives
- The acquisition of shares by the CEO as part of her bonus aligns her interests with those of the shareholders.
- The vesting of restricted stock awards is tied to the company's performance, incentivizing growth and value creation.
Negatives
- The disposal of shares to cover tax obligations, while common, slightly reduces the CEO's overall holdings.
Risks
- Failure to meet market capitalization or net sales growth targets could impact the vesting of restricted stock awards.
- Significant fluctuations in the stock price could affect the value of the CEO's holdings and potentially her motivation.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting of restricted stock awards is tied to future performance metrics like market capitalization and net sales growth.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing indicates the CEO's continued investment in the company's stock.
Stakeholder Impact
- Shareholders may view the CEO's stock transactions as a reflection of her confidence in the company.
- Employees may be motivated by the CEO's alignment with shareholder interests.
Key Dates
| Date | Description |
|---|---|
| 04/12/2022 | Initial vesting date for 200,000 restricted stock awards. |
| 12/31/2022 | End of fiscal year for net sales growth targets related to restricted stock awards. |
| 04/12/2023 | Second vesting date for 200,000 restricted stock awards. |
| 12/31/2023 | End of fiscal year for net sales growth targets related to restricted stock awards. |
| 03/13/2024 | Date of stock acquisition and disposition. |
| 04/12/2024 | Third vesting date for 200,000 restricted stock awards. |
| 12/31/2024 | End of fiscal year for net sales growth targets related to restricted stock awards. |
| 04/12/2025 | Final vesting date for 200,000 restricted stock awards. |
| 12/31/2025 | End of fiscal year for net sales growth targets related to restricted stock awards. |
| 03/15/2027 | Deadline for meeting market capitalization targets for restricted stock awards. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.